Improving Detection and Treatment of Locally Advanced Rectal Cancer by Dual Wavelength Quantitative Fluorescence Molecular Endoscopy Using Nivolumab-800CW and Durvalumab-680LT
Latest Information Update: 15 Mar 2024
At a glance
- Drugs Durvalumab (Primary) ; Nivolumab (Primary)
- Indications Rectal cancer
- Focus Adverse reactions; Diagnostic use
- Acronyms PREDICT
Most Recent Events
- 15 Mar 2024 New trial record